Introduction to Tagrisso
Tagrisso is a prescription anticancer medicine containing osimertinib as its active ingredient. It belongs to a group of targeted medicines known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. These medicines act on specific molecular pathways involved in cancer-cell growth and survival.
Tagrisso is used in selected treatment settings for non-small cell lung cancer (NSCLC) associated with particular EGFR gene mutations. Depending on the patient’s diagnosis and applicable product authorization, it may be prescribed after complete surgical removal of a tumor, following certain chemoradiation treatment, or for locally advanced or metastatic disease. In some circumstances, it may be used with pemetrexed and platinum-based chemotherapy.
The medicine is not appropriate for every person diagnosed with lung cancer. Treatment selection depends on molecular testing, disease stage, previous therapy, overall health and the current prescribing information applicable in the patient’s country.
This page explains the identity of Tagrisso, its active ingredient, medicine class, general clinical role, available strength information, administration principles and important precautions. It is intended to support understanding and informed discussions with healthcare professionals, not to replace professional medical advice.
What Is the Generic Name of Tagrisso?
The generic name of Tagrisso is osimertinib. The brand name identifies the marketed medicine, while the generic name identifies its active pharmaceutical ingredient.
Osimertinib inhibits specific mutant forms of EGFR. In some lung cancers, mutations in the EGFR gene cause abnormal signaling that promotes the growth and survival of cancer cells. By inhibiting susceptible forms of the receptor, osimertinib can interfere with these signals.
The presence of an EGFR mutation is an important part of treatment selection, but not every mutation qualifies a patient for every osimertinib indication. The relevant molecular result must be interpreted in the context of the cancer diagnosis and the applicable treatment criteria.
Patients should confirm that the medicine they have been prescribed contains the expected active ingredient and strength. A pharmacist can help explain the difference between a brand name, a generic name and a particular product presentation.
Medicine Classification and Type of Treatment
Tagrisso belongs to the EGFR tyrosine kinase inhibitor class. It is a targeted anticancer medicine rather than conventional cytotoxic chemotherapy.
Conventional chemotherapy and targeted therapy differ in how they act, although both can produce adverse effects and require medical supervision. Osimertinib is designed to inhibit particular altered forms of EGFR that contribute to certain lung cancers.
Its targeted action is especially relevant in cancers carrying activating mutations such as EGFR exon 19 deletions or the exon 21 L858R substitution. Osimertinib also has activity against the T790M resistance mutation, which can contribute to resistance to certain earlier EGFR inhibitors.
Targeted treatment is not risk-free. EGFR-related biological processes also have functions in healthy tissues, and osimertinib can cause clinically important adverse reactions. Patients require monitoring and should report concerning symptoms to their oncology team.
What Conditions Is Tagrisso Used For?
Tagrisso is used for defined treatment settings involving EGFR-mutated NSCLC. The exact indications depend on the local product authorization and the patient’s clinical circumstances.
Adjuvant Treatment Following Surgery
For eligible adults whose EGFR-mutated NSCLC has been completely removed surgically, Tagrisso may be prescribed as adjuvant treatment. Adjuvant treatment is given after the primary tumor has been removed to reduce the risk of recurrence.
The decision depends on the cancer stage, molecular findings, previous treatment and clinical assessment. The treating oncology team determines whether the expected benefits justify the potential risks.
Treatment After Chemoradiation
In certain adults with unresectable stage III NSCLC carrying specified EGFR mutations, Tagrisso may be prescribed following platinum-based chemoradiation when the disease has not progressed during or following that treatment.
This is a specific treatment setting with eligibility requirements. It should not be confused with treatment for every stage III lung cancer or with treatment of metastatic disease.
Locally Advanced or Metastatic NSCLC
Tagrisso may be used as an initial targeted treatment in eligible adults with locally advanced or metastatic NSCLC carrying specified activating EGFR mutations. In selected cases, it may be combined with pemetrexed and platinum-based chemotherapy.
The oncology team considers the mutation result, disease extent, treatment history, clinical condition and relevant prescribing information when choosing the regimen.
Metastatic T790M-Positive NSCLC
Osimertinib also has an established role in certain patients with metastatic NSCLC carrying the EGFR T790M mutation after progression during or following earlier EGFR tyrosine kinase inhibitor treatment. This indication depends on the applicable authorization and the patient’s circumstances.
Tagrisso is not a general medicine for every type of lung cancer and should not be presented as a treatment for unrelated cancers.
How Does Osimertinib Work?
EGFR is a receptor protein involved in cell signaling. Under normal circumstances, it participates in processes that regulate cell growth and division. Certain mutations can cause the receptor to remain abnormally active, allowing cancer cells to receive persistent growth signals.
Osimertinib inhibits susceptible mutant forms of EGFR by blocking their tyrosine kinase activity. This interferes with signaling pathways that contribute to cancer-cell growth and survival.
Its activity against selected EGFR mutations, including T790M, is clinically important because this mutation can contribute to resistance to some earlier targeted treatments.
The medicine’s effectiveness depends on the tumor’s molecular characteristics and other clinical factors. Some patients may experience disease control, while others may have limited benefit or develop resistance over time. Treatment response must therefore be evaluated through appropriate clinical assessment and investigations.
Tagrisso 80 mg: Product Strength and Formulation
The featured product on this website is Tagrisso 80 mg, an oral tablet containing 80 mg of osimertinib.
| Product detail | Information |
|---|---|
| Brand name | Tagrisso |
| Generic name | Osimertinib |
| Active ingredient | Osimertinib |
| Featured strength | 80 mg |
| Dosage form | Oral tablet |
| Medicine class | EGFR tyrosine kinase inhibitor |
| Treatment category | Targeted anticancer medicine |
| Company associated with the reference brand | AstraZeneca |
| Main treatment area | Selected EGFR-mutated NSCLC |
Other strengths or presentations may be available in particular markets. Availability, packaging and authorization should be checked against current official product information for the relevant country.
AstraZeneca is associated with the reference Tagrisso brand. The specific manufacturer, marketing authorization holder, importer and distributor may vary by product presentation and jurisdiction. These roles should be confirmed from the actual packaging and applicable official records rather than assumed.
General Dosage and Administration
The usual adult regimen described in official prescribing information is 80 mg taken orally once daily. The appropriate regimen may differ when a clinician determines that treatment modification is necessary because of adverse reactions or other clinical circumstances.
Patients should follow their own prescription and the instructions supplied with their product. They should not take extra tablets to compensate for a missed dose, change the dose independently or discontinue treatment without medical guidance.
Food and administration instructions should be checked against the current official patient leaflet for the specific product. Patients who are uncertain about swallowing the tablet, missed doses, vomiting after taking a dose or other practical concerns should contact their pharmacist or oncology team.
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Important Safety Considerations
Tagrisso can cause serious adverse reactions, including interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
Patients should promptly report new or worsening breathing difficulties, persistent cough, chest pain, fainting, a rapid or irregular heartbeat, significant eye pain or changes in vision. Severe or rapidly worsening symptoms may require emergency medical assessment.
The healthcare team may recommend symptom reviews, heart assessments, blood tests or other investigations according to the patient’s circumstances and the applicable prescribing information.
Before treatment, patients should discuss their medical history, existing heart or lung conditions and all medicines, vitamins, supplements and herbal products they use. Pregnancy, contraception and breastfeeding should also be discussed with a healthcare professional because specific precautions apply.
Common Side Effects
Possible side effects of Tagrisso include diarrhea, rash, dry skin, nail inflammation and mouth inflammation. Fatigue and reduced appetite may also occur in some patients.
The presence and severity of adverse effects vary between individuals. Persistent diarrhea, worsening skin reactions, difficulty eating or drinking, or symptoms that interfere with normal activities should be discussed with the healthcare team.
Patients should not assume that every new symptom is caused by Tagrisso. A healthcare professional can evaluate the possible cause and determine whether supportive care, additional tests or a treatment adjustment is necessary.
Drug Interactions and Medication Review
Other medicines can affect the safety of an osimertinib treatment regimen. Some drugs may influence heart rhythm, while others may affect medication metabolism or create additional risks when used together.
Patients should provide their oncology team with a complete list of prescription medicines, nonprescription products, vitamins and herbal supplements. They should not start a new medicine or supplement without checking whether it is appropriate during cancer treatment.
The healthcare professional can review potential interactions and decide whether any precautions, monitoring or treatment changes are necessary.
Product Identification and Manufacturer Information
When reviewing a Tagrisso package, patients should check the brand name, active ingredient, strength, dosage form, batch or lot number, expiry date and packaging condition. Manufacturer and other responsible-company details should be consistent with the relevant product documentation.
The reference Tagrisso brand is associated with AstraZeneca, but the organization responsible for manufacturing, authorization, importing or distributing a specific package must be confirmed from the actual label and applicable official records.
A brand name or package photograph alone cannot establish authenticity. Patients should obtain prescription medicines through legitimate supply channels and consult a pharmacist if the product’s identity or origin is uncertain.
Who May Be Prescribed Tagrisso?
Tagrisso may be prescribed to patients who meet the molecular and clinical requirements of an authorized treatment indication. Eligibility depends on the cancer diagnosis, EGFR mutation results, disease stage, previous treatment, other medical conditions and the expected balance of benefits and risks.
A diagnosis of lung cancer alone does not establish eligibility. Patients should not use another person’s prescription or assume that a treatment appropriate for one patient will be appropriate for another.
The oncology team can explain the purpose of treatment, anticipated monitoring, possible adverse reactions and available alternatives when relevant.
Frequently Asked Questions
Is Tagrisso a targeted therapy?
Yes. Osimertinib is an EGFR tyrosine kinase inhibitor designed to inhibit specific mutant forms of EGFR involved in certain lung cancers.
Is Tagrisso the same as osimertinib?
Tagrisso is the brand name, and osimertinib is its active ingredient.
Does Tagrisso treat all types of lung cancer?
No. It is used in defined settings involving specific EGFR mutations. Molecular testing and clinical assessment are necessary to establish eligibility.
What is the usual adult dose?
The usual adult regimen in official prescribing information is 80 mg once daily, but individual treatment decisions and any modifications must be made by a qualified healthcare professional.
Can Tagrisso cause serious adverse reactions?
Yes. Serious risks include lung inflammation, heart rhythm changes, cardiomyopathy and eye complications. Concerning symptoms should be assessed promptly.
Which company is associated with Tagrisso?
AstraZeneca is associated with the reference Tagrisso brand. Product-specific manufacturing and distribution information should be verified from the package and applicable official records.
Medical Disclaimer
The information on this page is provided for educational and informational purposes only. It does not replace professional medical advice, diagnosis, treatment or official prescribing information.
Always consult a qualified healthcare professional regarding your diagnosis, treatment options, dosage and use of prescription medicines. Do not start, stop or change treatment based solely on website content. For a medical emergency, seek immediate assistance from local emergency medical services.